Biodesix presents CLARIFY analysis on Nodify Lung test sequencing with PET imaging at CHEST 2026
BDSX•Biodesix said analyses from its CLARIFY study of more than 2,000 patients will be presented at CHEST 2026, pointing to added clinical value from sequencing Nodify Lung biomarkers with PET imaging.
1. CLARIFY study analyses
Biodesix flagged new real-world evidence on integrating Nodify Lung blood testing into routine pulmonary nodule care, slated for presentation at CHEST 2026. Analyses from the CLARIFY study of more than 2,000 tested patients point to added clinical value from sequencing biomarkers with PET imaging. Additional presentations indicate testing can influence care decisions, improve follow-up adherence and reduce reliance on more invasive diagnostics.
